接受同种异体造血细胞移植并在移植后使用环磷酰胺预防的老年人的疗效。

IF 2.3 3区 医学 Q2 HEMATOLOGY
Victoria Murillo, Paola Charry, María Suárez-Lledó, Laia Guardia, Cristina Moreno, Joan Cid, Miquel Lozano, Alexandra Pedraza, Raquel Salinas, Vanessa Vilas, Montserrat Duch, Marina Díaz-Beya, Laura Rosiñol, Jordi Esteve, Enric Carreras, Francesc Fernández-Avilés, Carmen Martínez, Montserrat Rovira, María Queralt Salas
{"title":"接受同种异体造血细胞移植并在移植后使用环磷酰胺预防的老年人的疗效。","authors":"Victoria Murillo,&nbsp;Paola Charry,&nbsp;María Suárez-Lledó,&nbsp;Laia Guardia,&nbsp;Cristina Moreno,&nbsp;Joan Cid,&nbsp;Miquel Lozano,&nbsp;Alexandra Pedraza,&nbsp;Raquel Salinas,&nbsp;Vanessa Vilas,&nbsp;Montserrat Duch,&nbsp;Marina Díaz-Beya,&nbsp;Laura Rosiñol,&nbsp;Jordi Esteve,&nbsp;Enric Carreras,&nbsp;Francesc Fernández-Avilés,&nbsp;Carmen Martínez,&nbsp;Montserrat Rovira,&nbsp;María Queralt Salas","doi":"10.1111/ejh.14291","DOIUrl":null,"url":null,"abstract":"<p>This study evaluates the feasibility of using post-transplant cyclophosphamide (PTCY) prophylaxis in allo-hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft-versus-host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty-seven adults aged 65 or older with hematological malignancies, undergoing their first allo-HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2-year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2-year overall survival, non-relapse mortality, cumulative incidence of relapse, and GVHD-free relapse-free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY-based allo-HCT in older adults.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"113 6","pages":"765-775"},"PeriodicalIF":2.3000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide based prophylaxis\",\"authors\":\"Victoria Murillo,&nbsp;Paola Charry,&nbsp;María Suárez-Lledó,&nbsp;Laia Guardia,&nbsp;Cristina Moreno,&nbsp;Joan Cid,&nbsp;Miquel Lozano,&nbsp;Alexandra Pedraza,&nbsp;Raquel Salinas,&nbsp;Vanessa Vilas,&nbsp;Montserrat Duch,&nbsp;Marina Díaz-Beya,&nbsp;Laura Rosiñol,&nbsp;Jordi Esteve,&nbsp;Enric Carreras,&nbsp;Francesc Fernández-Avilés,&nbsp;Carmen Martínez,&nbsp;Montserrat Rovira,&nbsp;María Queralt Salas\",\"doi\":\"10.1111/ejh.14291\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This study evaluates the feasibility of using post-transplant cyclophosphamide (PTCY) prophylaxis in allo-hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft-versus-host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty-seven adults aged 65 or older with hematological malignancies, undergoing their first allo-HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2-year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2-year overall survival, non-relapse mortality, cumulative incidence of relapse, and GVHD-free relapse-free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY-based allo-HCT in older adults.</p>\",\"PeriodicalId\":11955,\"journal\":{\"name\":\"European Journal of Haematology\",\"volume\":\"113 6\",\"pages\":\"765-775\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14291\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14291","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本研究评估了在 65 岁及以上成人异体造血细胞移植(HCT)中使用移植后环磷酰胺(PTCY)预防的可行性。PTCY越来越多地被用于预防所有供体类型的移植物抗宿主疾病(GVHD),但人们仍然担心其潜在风险,尤其是对老年患者而言。研究纳入了五十七位年龄在65岁或以上的成人血液恶性肿瘤患者,他们在2011年1月至2023年1月期间接受了首次allo-HCT,并使用了PTCY预防疗法。总体而言,94.8%的患者实现了初次移植。中性粒细胞和血小板移植的中位持续时间分别为19天和21天。第 +30 天细菌性血流感染的累计发生率为 43.9%。在使用来曲莫韦后的前 100 天内,没有发生 CMV 再激活。第+180天II-IV级和III-IV级急性GVHD累积发生率以及2年中度/重度慢性GVHD累积发生率分别为26.3%、10.5%和4.8%。18名患者(31.6%)复发,30名患者(52.6%)死亡,复发(16.4%)和感染(11.5%)是死亡的主要原因。估计的2年总生存率、非复发死亡率、复发累积发生率和无GVHD复发生存率分别为45.5%、27.1%、33.9%和37.0%。70岁或以上的成年人与65-69岁的成年人结果相似。这项研究证实了基于 PTCY 的异体肝移植在老年人中的安全性和可行性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide based prophylaxis

This study evaluates the feasibility of using post-transplant cyclophosphamide (PTCY) prophylaxis in allo-hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft-versus-host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty-seven adults aged 65 or older with hematological malignancies, undergoing their first allo-HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2-year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2-year overall survival, non-relapse mortality, cumulative incidence of relapse, and GVHD-free relapse-free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY-based allo-HCT in older adults.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
168
审稿时长
4-8 weeks
期刊介绍: European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信